![cover image](https://wikiwandv2-19431.kxcdn.com/_next/image?url=https://upload.wikimedia.org/wikipedia/commons/thumb/c/c6/Bi-specific_T-cell_engager.svg/640px-Bi-specific_T-cell_engager.svg.png&w=640&q=50)
Bi-specific T-cell engager
Class of artificial monoclonal antibodies / From Wikipedia, the free encyclopedia
Bi-specific T-cell engagers (BiTEs) are a class of artificial bispecific monoclonal antibodies that are investigated for use as anti-cancer drugs. They direct a host's immune system, more specifically the T cells' cytotoxic activity, against cancer cells. BiTE is a registered trademark of Micromet AG (fully owned subsidiary of Amgen Inc).[1]
![Thumb image](http://upload.wikimedia.org/wikipedia/commons/thumb/c/c6/Bi-specific_T-cell_engager.svg/220px-Bi-specific_T-cell_engager.svg.png)
BiTEs are fusion proteins consisting of two single-chain variable fragments (scFvs) of different antibodies, or amino acid sequences from four different genes, on a single peptide chain of about 55 kilodaltons. One of the scFvs binds to T cells via the CD3 receptor, and the other to a tumor cell via a tumor specific molecule.[2][3]